|
Report Date : |
29.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
TAI YU CHEMICAL & PHARMACEUTICAL CO.,
LTD. |
|
|
|
|
Registered Office : |
No.1, Alley 13, Lane 11, Yun San Rd., Chu
Tung Hsinchu |
|
|
|
|
Country : |
Taiwan |
|
|
|
|
Date of Incorporation : |
20.11.1973 |
|
|
|
|
Com. Reg. No.: |
47066452 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturing and sales of medical products
and medical device. |
|
|
|
|
No. of Employees : |
About 200 Employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Taiwan |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Taiwan ECONOMIC OVERVIEW
Taiwan has a dynamic capitalist economy with gradually decreasing government guidance of investment and foreign trade. Exports, led by electronics, machinery, and petrochemicals have provided the primary impetus for economic development. This heavy dependence on exports exposes the economy to fluctuations in world demand. In 2009, Taiwan's GDP contracted 1.8%, due primarily to a 13.1% year-on-year decline in exports. In 2010 GDP grew 10.7%, as exports returned to the level of previous years, and in 2011, grew 4.0%. In 2012, however, growth fell to 1.3%, because of softening global demand. Taiwan's diplomatic isolation, low birth rate, and rapidly aging population are major long-term challenges. Free trade agreements have proliferated in East Asia over the past several years, but except for the landmark Economic Cooperation Framework Agreement (ECFA) signed with China in June 2010, so far Taiwan has been excluded from this greater economic integration in part because of its diplomatic status. Negotiations continue on such follow-on components of ECFA regarding trade in goods and services. The MA administration has said that the ECFA will serve as a stepping stone toward trade pacts with other key trade partners, which Taiwan subsequently launched with Singapore and New Zealand. Taiwan's Total Fertility rate of just over one child per woman is among the lowest in the world, raising the prospect of future labor shortages, falling domestic demand, and declining tax revenues. Taiwan's population is aging quickly, with the number of people over 65 accounting for 11.2% of the island's total population as of 2012. The island runs a large trade surplus largely because of its surplus with China, and its foreign reserves are the world's fifth largest, behind China, Japan, Saudi Arabia, and Russia. In 2006 China overtook the US to become Taiwan's second-largest source of imports after Japan. China is also the island's number one destination for foreign direct investment. Three financial memorandums of understanding, covering banking, securities, and insurance, took effect in mid-January 2010, opening the island to greater investments from the mainland's financial firms and institutional investors, and providing new opportunities for Taiwan financial firms to operate in China. In August 2012, Taiwan Central Bank signed a memorandum of understanding on cross-Strait currency settlement with its Chinese counterpart. The MOU allows for the direct settlement of Chinese RMB and the New Taiwan dollar across the Strait, which could help develop Taiwan into a local RMB hub. Closer economic links with the mainland bring greater opportunities for the Taiwan economy, but also poses new challenges as the island becomes more economically dependent on China while political differences remain unresolved.
|
Source : CIA |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
No.1, Alley 13,
Lane 11, Yun San Rd., Chu Tung Hsinchu Taiwan |
|
Supplied Address: |
YUN-SAN RD NO. 1
ALLEY 13, LANE 11 CHUTUNG, HSINCHU R.O.C. TAIWAN |
|
Telephone Number: |
+886-3-582-6655 |
|
Fax Number: |
+886-3-582-2389 |
|
E-mail: |
Notes: The exact name and address are as above.
|
Credit Opinion: |
Subject was incorporated on 1973-11-20 with registered number 47066452 as Joint Stock Company in Taiwan.
|
Name |
Subscription Shares |
|
Shanjie Lin |
8,420 |
|
Peiling Lin |
|
|
4,125 |
|
The information above is that of subject’s major shareholders.
Related Companies
|
1 |
|
|
Name |
Hua Yu (Wu Xi) Pharmaceutical Co., Ltd |
|
Address |
No 1, 43 Mashan Mei Liang Road, Binhu District, Wuxi City, Jiangsu
Province, China |
|
Telephone Number |
+86-510-6607-6900 |
|
2 |
|
|
Name |
|
|
Address |
No 1, 43 Mashan Mei Liang Road, Binhu District, Wuxi City, Jiangsu
Province, China |
|
Telephone Number |
+86-510-6607-6900 |
Core
Management
|
1 |
|
|
Name |
Shanjie Lin |
|
Position |
Board Chairman |
|
2 |
|
|
Name |
Jinlian Xu |
|
Position |
Director |
|
3 |
|
|
Name |
Yanming Zheng |
|
Position |
Director |
|
4 |
|
|
Name |
Peiling Lin |
|
Position |
Supervisor |
Personnel
Structure
|
Total Employees |
About 200
Employees |
Offices
& Factories
|
|
Headquarters |
|
Add |
No.1, Alley 13, Lane 11, Yun San Rd., Chu
Tung Hsinchu Taiwan |
l
The subject is a manufacturer of medical products and medical device.
l
It is introduced that
subject has factory in Taiwan for production.
l
It is introduced that
subject has obtained GMP certification.
l
It is introduced that the
area of subject’s factory in Taiwan is about 10,000 square meters.
Purchase
Information
l
The registered activities of subject:
|
Business Code |
Details |
|
C110010 |
Manufacturing of drink |
|
C199990 |
Manufacturing of other uncategorized food |
|
C801030 |
Manufacturing of precision chemical
materials |
|
C802041 |
Manufacturing of western medicine |
|
C802060 |
Manufacturing of animal medicine |
|
C802100 |
Manufacturing of cosmetic |
|
C802990 |
Manufacturing of other chemical |
|
CF01011 |
Manufacturing of medical device |
|
F102040 |
Wholesale of drink |
|
F102170 |
Wholesale of food and groceries |
|
F107990 |
Wholesale of other chemical |
|
F108021 |
Wholesale of western medicine |
|
F108031 |
Wholesale of medical device |
|
F108040 |
Wholesale of cosmetic |
|
F203010 |
Retail of food, drink and groceries |
|
F207990 |
Retail of other chemical |
|
F208021 |
Retail of western medicine |
|
F208031 |
Retail of medical device |
|
F208040 |
Retail of cosmetic |
|
F401010 |
International trade business |
|
ZZ99999 |
Besides licensed business, all other
business items those are not banned or restricted. |
l
It is introduced that subject purchases raw
materials and etc both in domestic and overseas markets.
Sales
Information
l
The subject is mainly engaged in sales of medical products and medical device.
l
It is introduced that
subject’s selling territory is both at home and abroad.
l
It is introduced that
subject’s major customers are hospitals, healthcare centers, officina,
distributors of medical products and etc.
Major Products
|
|
Product |
|
1 |
Antibiotics (Penicillins, Cephalosporins,
Aminoglycosides, Other Antibiotics) |
|
2 |
Antibacterial Agents |
|
3 |
Antipyretics Analgesics &
Anti-inflammatories |
|
4 |
Antigout Agents |
|
5 |
Adrenocortical Hormones |
|
6 |
Antitussives Expectorants &
Antiasthmatics |
|
7 |
Common Cold preparations |
|
8 |
Antihistamine Agents |
|
9 |
Vitamins |
|
10 |
Hepatotonics & Antidotes |
|
11 |
Antihypertensive Agents |
|
12 |
Cardiotonics & Diuretics |
|
13 |
Anti-dizziness Agents |
|
14 |
Cerebral Metabolic Agents |
|
15 |
Spasmolytics |
|
16 |
Remedies of Peptic Ulcer |
|
17 |
Gastrointestinal Agents |
|
18 |
Antiemetics |
|
19 |
Hemostatic Agents |
|
20 |
Autonomic Agents |
|
21 |
Anti-Diabetic Agents |
|
22 |
Hormone Preparations |
|
23 |
Oxytocics |
|
24 |
Water, Nutrients and Electrolytes |
|
25 |
Metabolics & Electrolytes |
|
26 |
Local Anesthetics |
|
27 |
Dermatics |
Import and export
right:
|
Import right |
Yes |
|
Export right |
Yes |
Domestic Purchase
|
Payment
Terms |
Proportion |
|
|
Raw
materials and etc |
COD,
CBD, etc |
100% |
Foreign Purchase
|
Payment
Terms |
Proportion |
|
|
Raw
materials and etc |
CBD,
etc |
100% |
Sales
Domestic Markets
|
Sales
Terms |
Proportion |
|
|
Medical products and medical device. |
COD,
CBD, etc |
100% |
Export
|
Sales
Terms |
Proportion |
|
|
Medical products and medical device. |
CBD,
etc |
100% |
Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.
Subject’s relevant staff Ms. Long declined to disclose its financials citing the grounds of company’s confidentiality; from other source we can not obtain the relevant information, either.
|
Name |
Taipei Bank |
Mortgage
No chattel mortgage record of subject has been found within the recent 3
months.
Lawsuit
Up to date of reporting, no existing or latent litigation of the subject has been found.
|
Name |
Ms. Long |
|
Department |
Sales Department |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.68.36 |
|
UK Pound |
1 |
Rs.106.03 |
|
Euro |
1 |
Rs.91.47 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.